Acumen Pharmaceuticals, Inc. pushes research for brain health as dementia numbers climb

Acumen Pharmaceuticals, Inc. pushes research for brain health as dementia numbers climb
Acumen urges action on dementia

June marks Alzheimer and Brain Awareness Month, with more than 55 million people worldwide living with dementia, Acumen Pharmaceuticals, Inc. stated.

The biopharmaceutical company has reaffirmed its commitment to driving research advances and supporting those affected by neurological diseases. Acumen Pharmaceuticals, Inc. encourages individuals and families to engage with new initiatives and increase public awareness during this month dedicated to brain health.

Acumen Pharmaceuticals, Inc. recently published its first quarter financial results. The company outlined recent business developments in the update. Management continues to focus on advancing research in neurological diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.